Biogen has agreed to acquire Apellis Pharmaceuticals after an extended negotiation process. The company also entered a collaboration with Alloy Therapeutics focused on antisense drug development using ...

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by ...

Biogen Inc (NASDAQ:BIIB, XETRA:IDP) has been upgraded to ‘Buy’ from ‘Neutral’ by UBS analysts, who also raised their price ...

By Mariam Sunny April 29 (Reuters) - Biogen beat first-quarter expectations on Wednesday, as stronger sales of its ...

The Biogen/Dayra partnership is driven by the strategic potential of oral macrocyclic peptides. This emerging therapeutic approach aims to deliver biologic-like efficacy and safety in a convenient ...

Biogen cut its full-year profit forecast on Wednesday as it booked acquisition-related charges, although its first-quarter ...

Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the ...

(Reuters) -Biogen beat Wall Street estimates for third-quarter profit, helped by better-than-expected sales of some of its multiple sclerosis treatments. The company, however, cut its annual profit ...

Biogen Inc. (NASDAQ:BIIB) is one of the best stem cell therapy stocks to buy. On April 22, Biogen Inc. (NASDAQ:BIIB) was ...

This acquisition will add Syfovre and Empaveli to Biogen’s portfolio of medicines.

Biogen reported a strong Q1 2026 with $2.5 billion in revenue and growth product sales up 12%, while outlining financial impacts from its pending Apellis acquisition. Management expects a $120–$130 ...